EWTX

Edgewise is a pre-revenue, late-stage clinical biopharma whose entire value rests on its pipeline — the MD&A is explicit that the company has 'not generated any revenue to date' and the Risk Factors flag the business as 'substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500.' That binary character means traditional valuation (P/E, P/S) is uninformative; what matters is runway, burn, and trial readouts. On runway, the picture is strong: MD&A states $530.1M of cash and marketable securities at 2025-12-31, sufficient to 'fund our planned operating expenses and capital expenditure requirements through at least the next 12 months.' Balance-sheet quality is excellent — $522M of equity against just $30.3M of liabilities (0.06x), and current assets of $543M dwarf $27.4M of current liabilities.

However, the operating trajectory is deteriorating: net loss widened from $134M in FY2024 to $168M in FY2025 (-25.4% YoY), operating cash burn accelerated to -$144M (-31.9% YoY), and R&D rose 19.2% to $151M as sevasemten enters pivotal Becker trials and EDG-7500 progresses through a Phase 2 HCM trial. Share count grew 12.7% YoY to 107M — consistent with the disclosed April 2025 registered direct offering — and accumulated deficit deepened 44.3% to -$546M. The MD&A's own language signals more raises ahead: 'we will require substantial additional capital,' and 'raising additional capital may cause dilution to our stockholders.'